HealthQuill J&J
Johnson & Johnson has agreed to buy the rights for an investigational skin disorder treatment from Numab Therapeutics for $1.25 billion.
Drugs Health Pharma

J & J to buy rights for experimental skin disorder drug for $1.25 billion

Johnson & Johnson has agreed to buy the rights for an investigational skin disorder treatment from Numab Therapeutics for $1.25 billion.

Read More
FDA has granted full approval for Janssen Biotech’s Balversa drug to treat metastatic bladder cancer after clinical trials showed “significant” improvement in overall survival rates.
Drugs Health Pharma

J&J’s metastatic bladder cancer drug gets full FDA approval

HQ Team January 21, 2024: The FDA has granted full approval for Janssen Biotech’s Balversa drug to treat metastatic bladder cancer after clinical.

Read More
Johnson & Johnson will buy Ambrx Biopharma, Inc., a company developing targeted chemotherapy treatments, for $2 billion in cash.
Drugs Health Pharma

J&J to purchase Ambrx Biopharma for $2 billion in all-cash deal

HQ Team January 8, 2023: Johnson & Johnson will buy Ambrx Biopharma, Inc., a company developing targeted chemotherapy treatments, for $2 billion in cash..

Read More
Overuse of antibiotics
Drugs Health Pharma

J&J’s consumer division Kenvue floats $41bn IPO

Johnson & Johnson consumer arm Kenvue floats biggest US IPO since 2021. Kenvue is valued at $41bn after being divisioned off from US.

Read More
Phisiscal inactivity leading to spate of diseases
Pharma Uncategorized

J&J acquires cardio tech maker Abiomed for $16.6bn

J&J acquires cardiovascular medtech developer Abiomed for $16.6 billion

Read More